Lumacyte CEO on how real-time insight is driving down manufacturing failures and opening doors for more patients.

We spoke with Scott Jones, PhD, SVP & CSO at BioBridge Global (BBG) to understand the challenges of product-specific potency ...

"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...

The Cellares Cell Shuttle platform was the first to receive the FDA’s Advanced Manufacturing Technology (AMT) designation, which offers partners additional touchpoints and priority review mechanisms ...

Kincell Bio, a leading contract development and manufacturing organization (CDMO) in cell therapy, today announced the promotion of three accomplished executives to strengthen its leadership team and ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the works council consultation process regarding the wind-down of cell therapy activities has been completed and its Board of Directors ...